Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CANAKINUMAB Cause Renal failure? 340 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 340 reports of Renal failure have been filed in association with CANAKINUMAB (Ilaris). This represents 3.3% of all adverse event reports for CANAKINUMAB.

340
Reports of Renal failure with CANAKINUMAB
3.3%
of all CANAKINUMAB reports
91
Deaths
272
Hospitalizations

How Dangerous Is Renal failure From CANAKINUMAB?

Of the 340 reports, 91 (26.8%) resulted in death, 272 (80.0%) required hospitalization, and 305 (89.7%) were considered life-threatening.

Is Renal failure Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CANAKINUMAB. However, 340 reports have been filed with the FAERS database.

What Other Side Effects Does CANAKINUMAB Cause?

Pyrexia (1,327) Inappropriate schedule of drug administration (1,238) Drug ineffective (1,078) Inappropriate schedule of product administration (944) Pain (858) Condition aggravated (771) Malaise (684) Off label use (557) Arthralgia (555) Rash (505)

What Other Drugs Cause Renal failure?

OMEPRAZOLE (14,721) ESOMEPRAZOLE (14,633) LANSOPRAZOLE (12,509) PANTOPRAZOLE (11,543) EMTRICITABINE\TENOFOVIR DISOPROXIL (8,618) DEXLANSOPRAZOLE (6,618) TENOFOVIR DISOPROXIL (6,388) EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL (4,596) RABEPRAZOLE (3,135) LENALIDOMIDE (2,729)

Which CANAKINUMAB Alternatives Have Lower Renal failure Risk?

CANAKINUMAB vs CANDESARTAN CANAKINUMAB vs CANDESARTAN CILEXETIL CANAKINUMAB vs CANDESARTAN CILEXETIL\HYDROCHLOROTHIAZIDE CANAKINUMAB vs CANGRELOR CANAKINUMAB vs CANIS LUPUS FAMILIARIS SKIN

Related Pages

CANAKINUMAB Full Profile All Renal failure Reports All Drugs Causing Renal failure CANAKINUMAB Demographics